Huda Zoghbi, M.D. (Baylor College of Medicine, Houston)


Dr. Zoghbi is a professor in the departments of Human Genetics, Neurology, Neuroscience and Pediatrics at Baylor College of Medicine and an investigator with the Howard Hughes Medical Institute. Dr. Zoghbi is one of the leading neurogeneticists in the world. Her work has been instrumental in advancing the molecular understanding of neurological diseases using genetic tools. Dr. Zoghbi is an elected member of the Institute of Medicine.

Jeffrey Cummings, M.D. (UCLA) 

Dr. Cummings is the Augustus S. Rose Professor of Neurology and is also Professor of Psychiatry and Biobehavioral Sciences at UCLA. Dr. Cummings is Founder and Director of the UCLA Alzheimer’s Disease Center. The Center has an active clinical trials program and fosters imaging, genetics, clinical and neuroscience research. Dr. Cummings is Director of the UCLA Behavioral Neuroscience and Dementia Research Fellowship. Many of the approximately 40 fellows that he has trained currently hold leadership positions in dementia programs throughout the United States and the world. He is the Founder and Director of the Deane F. Johnson Center for Neurotherapeutics at UCLA. Dr. Cummings’ interests embrace clinical trials and the development of new treatments for neurodegenerative disorders and other neurological diseases. He is past president of the Behavioral Neurology Society and of the American Neuropsychiatric Association and in 2005 was named Edward Henderson State-of-the-Art Lecturer by the American Geriatrics Society. Dr. Cummings has authored or edited 20 books and over 450 peer reviewed papers. He has broad interests in dementing disorders, neuropsychiatry, neurotherapeutics, and the interface of neuroscience and society.

Peter T. Lansbury, Ph.D. (Harvard Medical School, Cambridge)

Dr. Lansbury is an associate professor of Neurology at the Harvard Medical School . He is director of the Brigham and Women’s Hospital Morris K. Udall Center of Excellence in Parkinson’s Disease Research and chair of the Harvard Laboratory for Drug Discovery in Neurodegeneration. Dr. Lansbury’s research is focused on the relationship between two characteristics of all neurodegenerative diseases; protein aggregation and neuronal death.

Donald L. Price, M.D. (Johns Hopkins University School of Medicine)

Dr. Donald L. Price, Professor of Pathology, Neurology and Neuroscience at Johns Hopkins Medical Institutions (JHMI), has made major contributions to the understanding of the mechanisms and potential therapeutic opportunities for a variety of human illnesses, particularly Alzheimer’s Disease (AD), Parkinson’s Disease (PD) and amyotrophic lateral sclerosis (ALS). Using transgenic approaches, he and his colleagues have created models of these neurodegenerative diseases and then have applied gene targeting to ablate proteins hypothesized to be critical in the pathogenesis of these human disorders. With these strategies, they have demonstrated that mice carrying mutant genes linked to familial AD, but lacking genes encoding individual secretase proteins, are protected from memory deficits and brain amyloidosis. Significantly, these discoveries are the basis for development of secretase inhibitors as anti-amyloid treatments. Thus, these models are proving to be of extraordinary value for testing novel therapies that, if efficacious in model systems, can be introduced into clinical trials. In recognition of his research, Dr. Price has received two Javits Neuroscience Investigator Awards from the NINDS, a Leadership and Excellence in Alzheimer’s Disease (LEAD) Award from the NIA, the Potamkin Prize for Research in Pick’s, Alzheimer’s and Related Disorders, and the MetLife Foundation Award for Alzheimer’s Disease. He is a member of the Institute of Medicine (National Academy of Sciences), and was President of the Society for Neuroscience (2000-2001). Author of over 500 publications in scientific journals, he was, according to Science Watch (12: 1-2, 2001), ranked in the top ten neuroscientists as Authors of High Impact Papers in Neuroscience during the “Decade of the Brain” (1990-2000).

*Participation by Dr. Price as a member of the Scientific Advisory Board does not constitute or imply endorsement by the Johns Hopkins University or the Johns Hopkins Hospital and Health System